🇺🇸 FDA
Patent

US 8143277

Method of using compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity

granted A61PA61P11/00A61P11/06

Quick answer

US patent 8143277 (Method of using compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity) held by Theravance, Inc. expires Mon Mar 22 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance, Inc.
Grant date
Tue Mar 27 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 22 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
26
CPC classes
A61P, A61P11/00, A61P11/06, A61P11/08, A61P11/16